Refine/Revise Search
Asking Price: $4,395,000

Three Highly Profitable Weight Loss Clinics

Not Disclosed, CT
Fairfield County

The business is a medical weight loss system developed by physicians, registered dietitians, and health professionals and covered by most medical insurance to help control the patient’s calorie and carbohydrate intake while eating the optimum amount of protein to preserve muscle mass. The system is a nationally recognized evidence-based program which will result in a successful lifestyle change. When administering the treatment, the clinics healthcare providers take each patient’s unique health profile into account to optimize their weight loss goals. The system has a 90% success rate for patients to achieve significant weight loss.The owner has opened and currently operates three franchisee clinics within the system. The first of the three opened in 2014.  The award winning franchisor system was established in 2006.The clinics cater to both corporate and individual clients. With 90% of the weight loss program’s cost typically covered by the patient’s medical insurance. The average patient completes the program in 10 weeks with many staying on for monthly maintenance visits. The program also offers additional revenue opportunities with supplement product sales as an additional growth area. This program is not a quick fix but a lifestyle change. The program teaches a balanced approach of education, appetite management and exercise activity to maximize weight loss. 

Cash Flow $1,117,804
Revenue $3,550,222
$ Owner Financing Available

Asking Price: $300,000

Medicare Certified Home Care Agency CHHA-Philadelp

Philadelphia, PA
Philadelphia County

HOME HEALTH CARE AGENCIES function in all States and are not medical, but rather administrative in nature. Hence, owner need not be a physician/ professional. It is a program that targets the elderly and is reimbursed by MediCare and Medicaid. State actually saves money by not having to pay for the nursing home bed (much more money on the average). THERE IS REALLY NO EXTENSIVE MARKETING INVOLVED, AS YOU ONLY NEED A FEW HUNDRED PEOPLE FOR STEADY BASE ENROLLMENT. The participants TYPICALLY use the service 3 TIMES WEEKLY FOR MANY YEARS. As long as they remain part of society, the government saves on long term care options. Currently, more than 22,000 agencies provide home care services to over 8 million clients because of physical disabilities, long-term health conditions, dementia, or terminal illnesses. Spending for home health care has risen from $3.5 billion in 1990 to $36 billion in 1999. Homecare providers deliver a wide variety of health care and supportive services. These can range from professional nursing and home health aide services to physical, occupational, respiratory, and speech therapies. Providers may be for-profit, non-profit (VNAs), or hospital based. ALL ARE IN THE AREAS HEAVILY OCCUPIED BY THE ELDERLY USERS OF THIS SERVICE. Application to the Program may be made directly by the Medicaid recipient, a family representative, or caregiver, the applicants personal physician or other interested parties acting on their behalf. This translates into self referring seniors, versus only those directed by a physician (as with most medical / govt subsidized services). And since they are not paying for it, the service is easy to ''sell''. THIS IS RECESSION PROOF BUSINESS AND USER BASE! WE WILL ANSWER ALL YOUR QUESTIONS AND TRAIN YOU ADEQUATELY FOR YOU TO FEEL SECURE AND COMPETENT.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

Asking Price: $20,000,000

Patented Universal Tumor-Targeting Drug Delivery

Irvine, CA
Orange County

Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

loading...
TOP ▲
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.